124 related articles for article (PubMed ID: 10981249)
1. Potential interaction between methotrexate and omeprazole.
Beorlegui B; Aldaz A; Ortega A; Aquerreta I; Sierrasesúmega L; Giráldez J
Ann Pharmacother; 2000 Sep; 34(9):1024-7. PubMed ID: 10981249
[TBL] [Abstract][Full Text] [Related]
2. Drug-drug interaction between methotrexate and levetiracetam resulting in delayed methotrexate elimination.
Bain E; Birhiray RE; Reeves DJ
Ann Pharmacother; 2014 Feb; 48(2):292-6. PubMed ID: 24259648
[TBL] [Abstract][Full Text] [Related]
3. Suspected methotrexate toxicity from omeprazole: a case review of carboxypeptidase G2 use in a methotrexate-experienced patient with methotrexate toxicity and a review of the literature.
McBride A; Antonia SJ; Haura EB; Goetz D
J Pharm Pract; 2012 Aug; 25(4):477-85. PubMed ID: 22550162
[TBL] [Abstract][Full Text] [Related]
4. Proton pump inhibitors inhibit methotrexate transport by renal basolateral organic anion transporter hOAT3.
Chioukh R; Noel-Hudson MS; Ribes S; Fournier N; Becquemont L; Verstuyft C
Drug Metab Dispos; 2014 Dec; 42(12):2041-8. PubMed ID: 25239859
[TBL] [Abstract][Full Text] [Related]
5. Use of plasma exchange in methotrexate removal in a patient with osteosarcoma and acute renal insufficiency.
Cecyn KZ; Lee J; Oguro T; Petrilli AS; Bordin JO
Am J Hematol; 2003 Mar; 72(3):209-11. PubMed ID: 12605394
[TBL] [Abstract][Full Text] [Related]
6. The pharmacokinetics of high-dose methotrexate in people living with HIV on antiretroviral therapy.
Dalla Pria A; Bendle M; Ramaswami R; Boffito M; Bower M
Cancer Chemother Pharmacol; 2016 Mar; 77(3):653-7. PubMed ID: 26696583
[TBL] [Abstract][Full Text] [Related]
7. Essential laboratory determinations for monitoring high-dose methotrexate treatment with citrovorum factor rescue.
Jürgens H; Ebell W; Bachmann R; Kupke I; Richter O; Andräs A; Göbel U
Pediatr Pharmacol (New York); 1983; 3(3-4):157-65. PubMed ID: 6610851
[TBL] [Abstract][Full Text] [Related]
8. A non-interventional retrospective cohort study of the interaction between methotrexate and proton pump inhibitors or aspirin.
Boerrigter E; Crul M
Ann Pharm Fr; 2017 Sep; 75(5):344-348. PubMed ID: 28705331
[TBL] [Abstract][Full Text] [Related]
9. Optimal management of methotrexate intoxication in a child with osteosarcoma.
Peyriere H; Cociglio M; Margueritte G; Vallat C; Blayac JP; Hillaire-Buys D
Ann Pharmacother; 2004 Mar; 38(3):422-7. PubMed ID: 14970366
[TBL] [Abstract][Full Text] [Related]
10. A Previously Unknown Drug-Drug Interaction Is Suspected in Delayed Elimination of Plasma Methotrexate in High-Dose Methotrexate Therapy.
Ishizaki J; Nakano C; Kitagawa K; Suga Y; Sai Y
Ann Pharmacother; 2020 Jan; 54(1):29-35. PubMed ID: 31416331
[No Abstract] [Full Text] [Related]
11. Reversible Impaired Methotrexate Clearance After Platinum-Based Chemotherapy for Osteosarcoma.
Oude Munnink T; van der Meer A; de Haan J; Touw D; van Kruchten M
Ther Drug Monit; 2019 Dec; 41(6):693-695. PubMed ID: 31169759
[TBL] [Abstract][Full Text] [Related]
12. High-dose methotrexate-doxycycline interaction.
Tortajada-Ituren JJ; Ordovás-Baines JP; Llopis-Salvia P; Jiménez-Torres NV
Ann Pharmacother; 1999; 33(7-8):804-8. PubMed ID: 10466909
[TBL] [Abstract][Full Text] [Related]
13. Delayed High-dose Methotrexate Excretion and Influencing Factors in Osteosarcoma Patients.
Zhang W; Zhang Q; Zheng TT; Zhen JC; Niu XH
Chin Med J (Engl); 2016 Nov; 129(21):2530-2534. PubMed ID: 27779157
[TBL] [Abstract][Full Text] [Related]
14. Delayed methotrexate clearance in osteosarcoma patients treated with multiagent regimens of neoadjuvant chemotherapy.
Bacci G; Ferrari S; Longhi A; Forni C; Loro L; Beghelli C; Tremosini M; Versari M
Oncol Rep; 2003; 10(4):851-7. PubMed ID: 12792734
[TBL] [Abstract][Full Text] [Related]
15. Severe intoxication with methotrexate possibly associated with concomitant use of proton pump inhibitors.
Santucci R; Levêque D; Kemmel V; Lutz P; Gérout AC; N'guyen A; Lescoute A; Schneider F; Bergerat JP; Herbrecht R
Anticancer Res; 2010 Mar; 30(3):963-5. PubMed ID: 20393020
[TBL] [Abstract][Full Text] [Related]
16. High-dose methotrexate: on the relationship of methotrexate elimination time vs renal function and serum methotrexate levels in 1164 courses in 264 Swedish children with acute lymphoblastic leukaemia (ALL).
Skärby T; Jönsson P; Hjorth L; Behrentz M; Björk O; Forestier E; Jarfelt M; Lönnerholm G; Höglund P
Cancer Chemother Pharmacol; 2003 Apr; 51(4):311-20. PubMed ID: 12721759
[TBL] [Abstract][Full Text] [Related]
17. Creatinine clearance rate and serum creatinine concentration are related to delayed methotrexate elimination in children with lymphoblastic malignancies.
Mao J; Zhang L; Shen H; Tang Y; Song H; Zhao F; Xu W
Neoplasma; 2014; 61(1):77-82. PubMed ID: 24195512
[TBL] [Abstract][Full Text] [Related]
18. Pralatrexate Monitoring Using a Commercially Available Methotrexate Assay to Avoid Potential Drug Interactions.
McPherson JP; Vrontikis A; Sedillo C; Halwani AS; Gilreath JA
Pharmacotherapy; 2016 Feb; 36(2):e8-e11. PubMed ID: 26809959
[TBL] [Abstract][Full Text] [Related]
19. Co-administration of proton pump inhibitors delays elimination of plasma methotrexate in high-dose methotrexate therapy.
Suzuki K; Doki K; Homma M; Tamaki H; Hori S; Ohtani H; Sawada Y; Kohda Y
Br J Clin Pharmacol; 2009 Jan; 67(1):44-9. PubMed ID: 19076159
[TBL] [Abstract][Full Text] [Related]
20. Methotrexate Associated Renal Impairment Is Related to Delayed Elimination of High-Dose Methotrexate.
Yang SL; Zhao FY; Song H; Shen DY; Xu XJ
ScientificWorldJournal; 2015; 2015():751703. PubMed ID: 26185782
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
